{"id":"stimulant","rwe":[],"_fda":{"id":"2bd4c72e-bec2-4b08-e063-6394a90a99ec","set_id":"6b256c8f-3953-4c69-9a16-ffa0511bdbcd","openfda":{"unii":["3FYP5M0IJX"],"route":["ORAL"],"rxcui":["200162","404318"],"spl_id":["2bd4c72e-bec2-4b08-e063-6394a90a99ec"],"brand_name":["Perdiem"],"spl_set_id":["6b256c8f-3953-4c69-9a16-ffa0511bdbcd"],"package_ndc":["0067-8143-01"],"product_ndc":["0067-8143"],"generic_name":["SENNOSIDES, STIMULANT LAXATIVE"],"product_type":["HUMAN OTC DRUG"],"substance_name":["SENNOSIDES"],"manufacturer_name":["Haleon US Holdings LLC"],"application_number":["M007"],"is_original_packager":[true]},"purpose":["Purpose Stimulant laxative"],"version":"7","stop_use":["Stop use and ask a doctor if rectal bleeding or failure to have a bowel movement occur after use of a laxative. These may be signs of a serious condition."],"warnings":["Warnings Do Not Use laxative products when abdominal pain, nausea or vomiting are present unless directed by a doctor for a period longer than 1 week unless directed by a doctor Ask Doctor before use if you have noticed a sudden change in bowel habits that persists over a period of 2 weeks Ask a doctor or pharmacist before use if you are taking any other drug. Laxatives may affect how other drugs work. Take this product 2 or more hours before or after other drugs. Stop use and ask a doctor if rectal bleeding or failure to have a bowel movement occur after use of a laxative. These may be signs of a serious condition. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away."],"questions":["Questions or comments? call 1-800-452-0051"],"ask_doctor":["Ask Doctor before use if you have noticed a sudden change in bowel habits that persists over a period of 2 weeks"],"do_not_use":["Do Not Use laxative products when abdominal pain, nausea or vomiting are present unless directed by a doctor for a period longer than 1 week unless directed by a doctor"],"effective_time":"20250116","active_ingredient":["Active Ingredient Sennosides 15 mg"],"inactive_ingredient":["Inactive ingredients acacia, calcium carbonate, carnauba wax, dibasic calcium phosphate dihydrate, magnesium stearate, methylparaben, microcrystalline cellulose, pharmaceutical ink, polyethylene glycol, polyvinyl alcohol, povidone, pregelatinized starch, propylparaben, silicon dioxide, sodium benzoate, sodium lauryl sulfate, sucrose, synthetic iron oxides, talc, titanium dioxide"],"indications_and_usage":["Uses relieves occasional constipation (irregularity) generally produces bowel movement in 6 to 12 hours"],"ask_doctor_or_pharmacist":["Ask a doctor or pharmacist before use if you are taking any other drug. Laxatives may affect how other drugs work. Take this product 2 or more hours before or after other drugs."],"spl_unclassified_section":["Other information ● each tablet contains: calcium 40 mg ● store at 20°C-25°C (68°F-77°F)."],"dosage_and_administration":["Directions take preferably before bedtime or as directed by a doctor. swallow tablet(s) with a glass of water swallow tablets whole, do not crush, break or chew Adults and children 12 years of age and older 2 tablets once or twice daily Children 6 to under 12 years of age 1 tablet once or twice daily Children under 6 years of age ask a doctor"],"spl_product_data_elements":["Perdiem Sennosides, stimulant laxative ACACIA CALCIUM CARBONATE CARNAUBA WAX DIBASIC CALCIUM PHOSPHATE DIHYDRATE MAGNESIUM STEARATE METHYLPARABEN MICROCRYSTALLINE CELLULOSE POLYETHYLENE GLYCOL 3350 POLYVINYL ALCOHOL, UNSPECIFIED POVIDONE, UNSPECIFIED STARCH, CORN PROPYLPARABEN SILICON DIOXIDE SODIUM BENZOATE SODIUM LAURYL SULFATE SUCROSE FERROUS OXIDE TALC TITANIUM DIOXIDE SENNOSIDES SENNOSIDES Perdiem Tan"],"keep_out_of_reach_of_children":["Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away."],"dosage_and_administration_table":["
Adults and children 12 years of age and older2 tablets once or twice daily
Children 6 to under 12 years of age1 tablet once or twice daily
Children under 6 years of ageask a doctor
"],"package_label_principal_display_panel":["Package/Label Principal Display Panel OVERNIGHT RELIEF Perdiem Sennosides 15 mg, Stimulant laxative A NATURAL VEGETABLE INGREDIENT NO MIXING NO MESS FORMULATED FOR DEPENDABLE OVERNIGHT RELIEF 60 Tablets Do not use if printed inner safety seal under cap is broken or missing. Perdiem 60 Tablets"]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"CONSTIPATION","source":"FDA FAERS","actionTaken":"12 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"10 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"8 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"7 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"6 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"6 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"6 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"5 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"5 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"5 reports"}]},"trials":[],"_chembl":null,"aliases":["long-acting methylphenidate, long-acting mixed amphetamine salts","Adderall","Concerta","Aptensio","Daytrana"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Stimulant","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:29:06.348750+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Stimulant","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:29:15.314460+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:29:26.410441+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:29:13.886294+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stimulant","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:29:14.647752+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:29:04.126623+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:29:21.669212+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:29:04.126679+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:29:16.198804+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL415111/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:29:15.206301+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"M007","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:29:04.126689+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"3fd9ba76-42f8-4ebe-b1bc-f81f08e702ce","title":"STOOL SOFTENER PLUS STIMULANT LAXATIVE (DOCUSATE SODIUM 50 MG AND SENNOSIDES 8.6 MG) TABLET, FILM COATED [CARDINAL HEALTH, 110 DBA LEADER]"},"aiSummary":"Stimulant, developed by Florida International University, is a marketed drug primarily indicated for occasional constipation relief. Its key composition patent is set to expire in 2028, providing a period of exclusivity and potential market protection. The primary risk is the lack of revenue data and key trial results, which may limit investor confidence and market adoption.","ecosystem":[],"_scrapedAt":"2026-03-28T00:09:46.859Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Stimulant","title":"Stimulant","extract":"Stimulants are a class of psychoactive drugs that increase alertness. They are used for various purposes, such as enhancing attention, motivation, cognition, mood, and physical performance. Some stimulants occur naturally, while others are exclusively synthetic. Common stimulants include caffeine, nicotine, cocaine, amphetamine/methamphetamine, methylphenidate, and modafinil. Stimulants may be subject to varying forms of regulation, or outright prohibition, depending on jurisdiction. Most stimulants are highly addictive and damage health when addicted."},"references":[],"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T01:29:26.410605+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"indications":{"approved":[{"id":"stimulant-occasional-constipation-relief","name":"Occasional constipation relief","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Not specified","pivotalTrial":null,"restrictions":[],"patientPopulation":"Not specified","diagnosticRequired":null,"brandNameForIndication":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03485417","phase":"PHASE2, PHASE3","title":"Substance Misuse To Psychosis for Stimulants","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-06-01","conditions":"Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis), Schizophrenia and Related Disorders, Stimulant Dependence","enrollment":165},{"nctId":"NCT04734080","phase":"PHASE4","title":"Dronabinol in Total Knee Arthroplasty (TKA)","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2021-03-09","conditions":"Total Knee Arthroplasty, Opioid Use","enrollment":114},{"nctId":"NCT07179614","phase":"NA","title":"Kentucky Women's Justice Community Overdose Innovation Network - Phase II","status":"NOT_YET_RECRUITING","sponsor":"Michele Staton","startDate":"2026-04-15","conditions":"Overdose Risk, Opioid Use Disorder, Stimulant Use Disorders","enrollment":300},{"nctId":"NCT07490717","phase":"NA","title":"Developing and Testing Innovative Care Pathways for Screening and Treatment of OUD/PTSD in Jails","status":"ENROLLING_BY_INVITATION","sponsor":"University of Arkansas","startDate":"2026-01-20","conditions":"Post-traumatic Stress Disorder (PTSD), Post-traumatic Stress Symptoms, Opioid Use Disorder (OUD)","enrollment":338},{"nctId":"NCT07484217","phase":"PHASE3","title":"Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2026-02-23","conditions":"Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms","enrollment":508},{"nctId":"NCT01571752","phase":"","title":"Health Outcomes by Neighborhood - Baltimore","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2012-07-17","conditions":"Stigma, Activity Space, Social Networks","enrollment":1651},{"nctId":"NCT07479771","phase":"NA","title":"tTIS Targeted of the Striatum as an Intervention for MUD Patients","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2026-03-26","conditions":"Amphetamine Use Disorders","enrollment":60},{"nctId":"NCT07221396","phase":"NA","title":"LDART for Stimulant Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-04-01","conditions":"Stimulant Use Disorder, Cocaine Use Disorder, Methamphetamine Use Disorder","enrollment":80},{"nctId":"NCT06871488","phase":"PHASE4","title":"Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-03-05","conditions":"ADHD - Attention Deficit Disorder With Hyperactivity, Irritability, Aggression Childhood","enrollment":136},{"nctId":"NCT07125235","phase":"NA","title":"Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-02-09","conditions":"Behavioral Intervention, Viral Suppression of HIV Infection, ART Adherence","enrollment":270},{"nctId":"NCT07281378","phase":"NA","title":"Reducing Co-occurring Substance Use and HIV Risk Among Stimulant-using Men at High Risk for HIV in the United States of America.","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-04-15","conditions":"Drug Use Disorders, PrEP Uptake, PrEP Adherence","enrollment":84},{"nctId":"NCT07226219","phase":"PHASE1","title":"Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-11-25","conditions":"Sickle Cell Disease, Executive Dysfunction, Cognitive Impairment","enrollment":72},{"nctId":"NCT07461350","phase":"","title":"Stimulant and Polysubstance Use, Inflammation, and Sex Effects on Myocardial Disease in HIV","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-03-15","conditions":"HIV (Human Immunodeficiency Virus)","enrollment":400},{"nctId":"NCT07314333","phase":"PHASE1","title":"A Trial to Assess How Centanafadine Interacts With Stimulants in the Body","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-02-05","conditions":"ADHD","enrollment":42},{"nctId":"NCT05783817","phase":"PHASE2","title":"MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)","status":"RECRUITING","sponsor":"Carolyn Rodriguez","startDate":"2025-09-10","conditions":"Obsessive-Compulsive Disorder","enrollment":40},{"nctId":"NCT07443332","phase":"NA","title":"Culturally Adapted Contingency Management","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03","conditions":"Stimulant Use Disorders","enrollment":70},{"nctId":"NCT03434509","phase":"NA","title":"Ongoing Tai Chi Training for Children With ADHD","status":"COMPLETED","sponsor":"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.","startDate":"2017-11-02","conditions":"ADHD","enrollment":15},{"nctId":"NCT07365293","phase":"NA","title":"Testing Implementation Strategies to Scale-up a Multicomponent Continuum of Service Intervention for Families Involved in Systems With Parental Opioid and Methamphetamine Use","status":"RECRUITING","sponsor":"Chestnut Health Systems","startDate":"2026-02-12","conditions":"Substance Related Disorders","enrollment":254},{"nctId":"NCT06356311","phase":"PHASE3","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-03","conditions":"Gastroesophageal Cancer","enrollment":450},{"nctId":"NCT07425964","phase":"NA","title":"Sleep Hygiene Education to Improve Sleep in Chronic Migraine and Back Pain","status":"NOT_YET_RECRUITING","sponsor":"Aalborg University","startDate":"2026-02","conditions":"Migraine Disorder, Low Back Pain, Chronic Pain","enrollment":100},{"nctId":"NCT06788587","phase":"PHASE2","title":"Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2025-07-18","conditions":"Methamphetamine Abuse, Methamphetamine-dependence, Addiction","enrollment":80},{"nctId":"NCT06637423","phase":"PHASE1, PHASE2","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-20","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":32},{"nctId":"NCT06370481","phase":"NA","title":"HIV, Equity, and Addiction Training (HEAT) Program","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-01-29","conditions":"Substance Use Disorders, Hiv, Opioid Use Disorder","enrollment":30},{"nctId":"NCT07407114","phase":"NA","title":"Effects of Different Stimuli on Muscle Activation, Hand Grip Strength, Reaction Time, and Hand Function","status":"COMPLETED","sponsor":"Lokman Hekim University","startDate":"2023-03-30","conditions":"Upper Extremity Dysfunction","enrollment":80},{"nctId":"NCT07136363","phase":"NA","title":"RESTORE Study R61 Phase: Recovery and Engagement for Stimulant Users on Re-entry","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-04-06","conditions":"HIV, Stimulant Use Disorder, Justice Involved Populations","enrollment":40},{"nctId":"NCT05972044","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2023-07-06","conditions":"ADHD","enrollment":516},{"nctId":"NCT03904186","phase":"NA","title":"Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-12-19","conditions":"Human Immunodeficiency Virus, Smoking Cessation, Smoking, Cigarette","enrollment":131},{"nctId":"NCT07398365","phase":"","title":"Medical Phenotyping of NHS General Adult Psychiatry (GAP) Inpatients","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2024-04-03","conditions":"Bipolar Affective Disorder, Schizophrenia Disorders, Depression Disorders","enrollment":100},{"nctId":"NCT06790576","phase":"PHASE1","title":"Optimizing Transcranial Magnetic Stimulation for Stimulant Use Disorder","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2024-12-01","conditions":"Stimulant Use Disorder","enrollment":50},{"nctId":"NCT04899024","phase":"NA","title":"PrEP Affect Regulation Treatment Innovation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Florida International University","startDate":"2022-01-31","conditions":"Medication Adherence, HIV Prevention, Stimulant Use","enrollment":239},{"nctId":"NCT05854667","phase":"PHASE2","title":"Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2023-12-05","conditions":"Methamphetamine Abuse, Methamphetamine-dependence, Addiction, Substance","enrollment":440},{"nctId":"NCT07380412","phase":"NA","title":"A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications","status":"RECRUITING","sponsor":"Outliers, Inc.","startDate":"2025-08-12","conditions":"ADHD, Sleep Disturbance, Brain Fog","enrollment":90},{"nctId":"NCT07153549","phase":"NA","title":"Biolizin for Improving Functional Poor Appetite in Children Aged 6 to 36 Months (CTBE2502)","status":"RECRUITING","sponsor":"Haiphong University of Medicine and Pharmacy","startDate":"2025-09-20","conditions":"Feeding and Eating Disorders of Childhood, Appetite Disorders, Functional Poor Appetite","enrollment":110},{"nctId":"NCT03221543","phase":"NA","title":"Resting Metabolic Rate Testing in Bariatric Surgery Patients","status":"TERMINATED","sponsor":"Baylor Research Institute","startDate":"2017-07-31","conditions":"Weight Loss, Bariatric Surgery Candidate","enrollment":84},{"nctId":"NCT05493475","phase":"NA","title":"Evaluation of a Novel Intervention to Prevent Polysubstance Overdoses Involving Illicit Stimulants","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2022-11-10","conditions":"Opiate Overdose, Fentanyl Overdose, Harm Reduction","enrollment":653},{"nctId":"NCT05592119","phase":"","title":"Effect of Stimulant Medication on Loss of Control Eating in Youth With Attention Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Nova Scotia Health Authority","startDate":"2023-01-11","conditions":"Loss of Control Eating, Attention Deficit/Hyperactivity Disorder","enrollment":10},{"nctId":"NCT06444360","phase":"NA","title":"Behavioral Activation and Risk Reduction for Stimulant Use Among Sexually Active Adolescents and Young Adults","status":"RECRUITING","sponsor":"Westat","startDate":"2025-11-04","conditions":"HIV","enrollment":360},{"nctId":"NCT07333339","phase":"","title":"A Brain-Computer Interface-Based Attention Training Program Compared With Methylphenidate and Citicoline","status":"COMPLETED","sponsor":"Uludag University","startDate":"2025-02-01","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Brain Computer Interface","enrollment":174},{"nctId":"NCT05776056","phase":"PHASE4","title":"Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-02-05","conditions":"Posttraumatic Stress Disorder (PTSD)","enrollment":70},{"nctId":"NCT06360419","phase":"PHASE3","title":"Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2024-03-18","conditions":"Major Depressive Disorder","enrollment":346},{"nctId":"NCT07309588","phase":"PHASE1, PHASE2","title":"Hyaluronic Acid in the Treatment of Hyposalivation","status":"ENROLLING_BY_INVITATION","sponsor":"Poznan University of Medical Sciences","startDate":"2025-07-01","conditions":"Xerostomia Due to Hyposecretion of Salivary Gland","enrollment":100},{"nctId":"NCT05546515","phase":"PHASE2","title":"Suvorexant for Opioid/Stimulant Co-use","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-12-01","conditions":"Opioid Use Disorder, Stimulant Use Disorder","enrollment":20},{"nctId":"NCT05322954","phase":"PHASE1","title":"Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-03-03","conditions":"Methamphetamine Use Disorder, Substance-Related Disorders, Chemically-Induced Disorders","enrollment":12},{"nctId":"NCT05301361","phase":"PHASE1","title":"Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, Davis","startDate":"2023-02-01","conditions":"Intellectual Disability, Fragile X Syndrome, Down Syndrome","enrollment":68},{"nctId":"NCT04982796","phase":"PHASE1, PHASE2","title":"Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder","status":"RECRUITING","sponsor":"Portland VA Research Foundation, Inc","startDate":"2022-07-07","conditions":"Amphetamine-Related Disorders","enrollment":30},{"nctId":"NCT06221358","phase":"","title":"Pharmacogenomics of Stimulant Treatment Response","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2024-04-01","conditions":"Attention-Deficit/ Hyperactivity Disorder (ADHD)","enrollment":400},{"nctId":"NCT07260734","phase":"","title":"AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)","status":"NOT_YET_RECRUITING","sponsor":"Imperial College London","startDate":"2025-12-01","conditions":"OESOPHAGO-GASTRIC CARCINOMA, Oesophageal Adenocarcinoma, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma","enrollment":6000},{"nctId":"NCT07251348","phase":"NA","title":"Progressive Relaxation and Psychoeducation in Patients With Hematological Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Necmettin Erbakan University","startDate":"2026-02-01","conditions":"Hematological Cancer","enrollment":75},{"nctId":"NCT06878976","phase":"PHASE3","title":"Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder","status":"ENROLLING_BY_INVITATION","sponsor":"Axsome Therapeutics, Inc.","startDate":"2025-02-20","conditions":"Binge-Eating Disorder","enrollment":300},{"nctId":"NCT06568367","phase":"PHASE3","title":"Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2024-08-01","conditions":"Excessive Sleepiness, Shift-work Disorder","enrollment":520},{"nctId":"NCT06413433","phase":"PHASE3","title":"Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2024-04-26","conditions":"Binge-Eating Disorder","enrollment":450},{"nctId":"NCT07238465","phase":"PHASE3","title":"Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-12","conditions":"Down Syndrome, Autonomic Dysfunction","enrollment":200},{"nctId":"NCT06165198","phase":"NA","title":"Individualized Neuromodulation for the Core Clinical Features of Drug Addiction","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2023-09-25","conditions":"Amphetamine Use Disorders","enrollment":9},{"nctId":"NCT05185583","phase":"PHASE2","title":"Methylphenidate in Childhood Apraxia of Speech","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-03-14","conditions":"Childhood Apraxia of Speech","enrollment":18},{"nctId":"NCT07216963","phase":"NA","title":"The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-09","conditions":"Opioid Use Disorder, Overdose, Drug, Overdose","enrollment":400},{"nctId":"NCT06033365","phase":"NA","title":"Beginning Early and Assertive Treatment for Methamphetamine Use Disorder","status":"COMPLETED","sponsor":"Denver Health and Hospital Authority","startDate":"2023-04-11","conditions":"Methamphetamine Use Disorder","enrollment":192},{"nctId":"NCT07043452","phase":"EARLY_PHASE1","title":"Measuring Acute Drug Demand in Humans II","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2025-11-15","conditions":"Healthy Volunteers","enrollment":""},{"nctId":"NCT04501653","phase":"EARLY_PHASE1","title":"Precision Functional Brain Mapping in Psilocybin","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-06-01","conditions":"Psilocybin","enrollment":11},{"nctId":"NCT06513156","phase":"NA","title":"Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use","status":"RECRUITING","sponsor":"Elana Rosenthal","startDate":"2024-10-01","conditions":"Opioid Use Disorder, Injection Related Infections, Stimulant Use Disorder","enrollment":304},{"nctId":"NCT03814356","phase":"PHASE1","title":"Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-08-24","conditions":"Brain Injury Traumatic Severe (Diagnosis), Coma, Consciousness, Level Altered","enrollment":10},{"nctId":"NCT05916339","phase":"PHASE4","title":"AWARE: Management of ADHD in Autism Spectrum Disorder","status":"RECRUITING","sponsor":"Daniel Coury","startDate":"2023-10-01","conditions":"ADHD, Autism Spectrum Disorder","enrollment":500},{"nctId":"NCT07219082","phase":"NA","title":"Behavioral Safety and Fentanyl Education: BSAFE","status":"NOT_YET_RECRUITING","sponsor":"San Francisco Department of Public Health","startDate":"2025-12-15","conditions":"Drug Overdose, Drug Overdose Accidental","enrollment":160},{"nctId":"NCT04903470","phase":"NA","title":"Defecation Patterns in Constipated Patients","status":"RECRUITING","sponsor":"The California Medical Innovations Institute, Inc.","startDate":"2022-12-19","conditions":"Constipation by Outlet Obstruction","enrollment":130},{"nctId":"NCT06564792","phase":"NA","title":"Contingency Management in HIV Care for Both Stimulant Use & ART Adherence","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2023-09-15","conditions":"Stimulant Use (Diagnosis), Hiv","enrollment":37},{"nctId":"NCT06038929","phase":"NA","title":"Effect of Vagal Nerve Stimulation on Gastric Motor Functions","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-09-01","conditions":"Depression, Epilepsy","enrollment":16},{"nctId":"NCT06899594","phase":"EARLY_PHASE1","title":"Psilocybin for Methamphetamine Addiction","status":"RECRUITING","sponsor":"Kevin Murnane","startDate":"2025-04-04","conditions":"Methamphetamine Use Disorder","enrollment":20},{"nctId":"NCT06646822","phase":"","title":"Prevalence, Awareness, Attitudes and Patterns of Stimulant Drug Use Among Students in Egyptian Universities","status":"ACTIVE_NOT_RECRUITING","sponsor":"Asmaa Ahmed Hamed Mohie Eldin","startDate":"2024-12-10","conditions":"Study of Stimulants in Egypt","enrollment":1500},{"nctId":"NCT04299490","phase":"PHASE2","title":"Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-11-11","conditions":"Sleep Disorder, Healthy","enrollment":148},{"nctId":"NCT05976984","phase":"","title":"Stimulant Overdose in the Medicaid Population: Who is at Risk, and When Are They at Risk","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2021-09-30","conditions":"Stimulant Overdose","enrollment":634939},{"nctId":"NCT07183254","phase":"NA","title":"Resting-state Imaging and Chronic Consumption of Non-Nutritive SweetenerS","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2025-10-01","conditions":"Healthy Volunteers - Male and Female","enrollment":100},{"nctId":"NCT06175273","phase":"PHASE2, PHASE3","title":"Pediatric Oncology Nutrition Intervention Trial","status":"COMPLETED","sponsor":"Corey Hawes","startDate":"2024-01-31","conditions":"Pediatric Cancer, Nutrition Related Cancer, Nutrition Aspect of Cancer","enrollment":19},{"nctId":"NCT07178496","phase":"NA","title":"Sleep Hygiene Plus Physiotherapy for Sleep and Disability in Chronic Neck Pain","status":"NOT_YET_RECRUITING","sponsor":"Al-Azhar University","startDate":"2025-10-15","conditions":"Neck Pain, Neck Pain Musculoskeletal, Sleep Disturbances","enrollment":120},{"nctId":"NCT05787847","phase":"NA","title":"Financial Incentives to Promote Stimulant Abstinence in a Community-Based Syringe Exchange Program","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2024-02-14","conditions":"Stimulant Use","enrollment":27},{"nctId":"NCT06538584","phase":"PHASE1, PHASE2","title":"Dex +/- Caffeine Sedation in a Post-MRI Recovery in a Pediatric Population","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-09-09","conditions":"Enhanced Recovery After Surgery in a Pediatric Population","enrollment":100},{"nctId":"NCT06578429","phase":"NA","title":"Deep TMS of Neural Circuits Associated With Stimulant Use Disorder","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-03-15","conditions":"Methamphetamine Use Disorder, Transcranial Magnetic Stimulation","enrollment":30},{"nctId":"NCT06814275","phase":"NA","title":"Project neuroARTEMIS","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2025-04-29","conditions":"Stimulant Use, Human Immunodeficiency Virus (HIV), Depression","enrollment":189},{"nctId":"NCT05288751","phase":"NA","title":"Contingency Management for Opioid and Stimulant Use Disorders in Primary Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Minnesota","startDate":"2022-06-15","conditions":"Opioid Use Disorder, Stimulant Use Disorder","enrollment":56},{"nctId":"NCT06444256","phase":"PHASE2","title":"Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2024-07-25","conditions":"Stimulant Use Disorder","enrollment":20},{"nctId":"NCT04228276","phase":"NA","title":"Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2021-02-05","conditions":"Stimulant Use Disorder, Substance-related Disorders","enrollment":30},{"nctId":"NCT03279952","phase":"PHASE4","title":"Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2018-06-01","conditions":"ADHD","enrollment":11},{"nctId":"NCT07128485","phase":"NA","title":"Remote Fentanyl Test Strip Distribution and Education to Prevent Drug Overdose","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-09","conditions":"Accidental Overdose of Opiate","enrollment":100},{"nctId":"NCT07127237","phase":"EARLY_PHASE1","title":"Prucaloprida vs Bisacodyl as a Stimulant in Bowel Preparation for Video Colonoscopy in Adults","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clínicas Dr. Manuel Quintela","startDate":"2025-09","conditions":"Bowel Preparation","enrollment":124},{"nctId":"NCT07112105","phase":"NA","title":"Repetitive Transcranial Magnetic Stimulation Treatment of Stimulant Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-01-01","conditions":"Stimulant Use Disorder","enrollment":106},{"nctId":"NCT03511976","phase":"PHASE4","title":"Adaptive Response to Intervention (RTI) for Students With ADHD","status":"WITHDRAWN","sponsor":"Florida International University","startDate":"2018-05-14","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":""},{"nctId":"NCT05958017","phase":"NA","title":"reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-03-04","conditions":"Stimulant Use Disorder, People Living With HIV, reSET","enrollment":500},{"nctId":"NCT07092059","phase":"NA","title":"Smartphone Services for Stimulant Use Disorder","status":"RECRUITING","sponsor":"DynamiCare Health","startDate":"2025-06-24","conditions":"Stimulant Use Disorder","enrollment":270},{"nctId":"NCT04281979","phase":"NA","title":"Effects of a Specific Substance in Smokers","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2020-02-25","conditions":"Smoking","enrollment":60},{"nctId":"NCT06221722","phase":"","title":"Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-11-01","conditions":"Constipation - Functional, Refractory Constipation, Fluoxetine","enrollment":150},{"nctId":"NCT06981533","phase":"NA","title":"Auricular Acupressure for Premenstrual Syndrome in Female Students","status":"COMPLETED","sponsor":"University of Medicine and Pharmacy at Ho Chi Minh City","startDate":"2025-04-20","conditions":"Premenstrual Syndrome","enrollment":66},{"nctId":"NCT06609278","phase":"NA","title":"THRIVE: Culturally AdapTed Harm Reduction Intervention","status":"COMPLETED","sponsor":"Brittany Miller-Roenigk","startDate":"2025-04-02","conditions":"Opioid Use, Stimulant Use","enrollment":57},{"nctId":"NCT07061886","phase":"EARLY_PHASE1","title":"Drug Effects on Mood and Behavior - Expectancy","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-06-26","conditions":"LSD","enrollment":48},{"nctId":"NCT03680287","phase":"PHASE2","title":"Effects of Sleep Disruption on Drug Response","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2019-10-07","conditions":"Low Back Pain, Recurrent, Healthy","enrollment":109},{"nctId":"NCT04907357","phase":"NA","title":"rTMS for Stimulant Use Disorders","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2022-02-04","conditions":"Cocaine Use Disorder, Methamphetamine Abuse, Cocaine Dependence","enrollment":129},{"nctId":"NCT04205487","phase":"NA","title":"PrEP Readiness Interventions for Supporting Motivation","status":"COMPLETED","sponsor":"Florida International University","startDate":"2020-10-16","conditions":"HIV Infections, Pre-exposure Prophylaxis, Substance Use Disorders","enrollment":70},{"nctId":"NCT07024303","phase":"EARLY_PHASE1","title":"Measurement of Treatment Effects","status":"NOT_YET_RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2025-06-15","conditions":"Challenging Behavior, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT06910605","phase":"NA","title":"Exploring Parameters of Driving Simulation in Relation to Drug Holidays in ADHD Patients","status":"RECRUITING","sponsor":"Stefan Lakämper","startDate":"2025-06-02","conditions":"ADHD - Attention Deficit Disorder With Hyperactivity, Driving Simulator Performance, ADHD","enrollment":26},{"nctId":"NCT06969066","phase":"NA","title":"Memory Training in Insomnia With Cognitive Impairment","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-11-01","conditions":"Cognitive Therapy/Methods, Insomnia Chronic, Cognitive Dysfunction","enrollment":70},{"nctId":"NCT06967922","phase":"NA","title":"Impact of Analytic-integrative Cognitive Behavioural Therapy on Acute Insomnia Disorder (Stress)","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-11-01","conditions":"Acute Insomnia Disorder","enrollment":70},{"nctId":"NCT06967974","phase":"NA","title":"Effects of Tai Chi on Chronic Insomnia Disorder Combined With Hyperarousal/Anxiety","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-11-01","conditions":"Chronic Insomnia","enrollment":80},{"nctId":"NCT06969079","phase":"NA","title":"Ba Duan Jin for CI With Hyperarousal/Anxiety","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-11-01","conditions":"Mind-Body Therapies, Insomnia Chronic","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral"},"crossReferences":{"chemblId":"CHEMBL415111"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":20873,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Stimulant","genericName":"Stimulant","companyName":"Florida International University","companyId":"florida-international-university","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T01:29:26.410605+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}